Impact of cGVHD on late relapse and survival 2 Translational relevance: Clinical evidence implicates graft-versus-host disease (GVHD) in enhancing malignancy control. We focused here on assessing chronic GVHD effects in 7,489 patients who were alive and free of disease at one year post-transplant. The current study demonstrates the protective effect of chronic GVHD on late relapse only in patients with CML.
Introduction
Allogeneic hematopoietic cell transplantation (HCT) following myeloablative conditioning (MAC) regimen is a standard and curative treatment option for hematologic malignancies (1) .
The anti-leukemic activity of MAC and allogeneic HCT relies not only on the effects of high dose chemotherapy or irradiation given during the conditioning regimen, but also on the immune-mediated graft-versus leukemia (GVL) effect (2) (3) (4) . The immune reactivity between donor T cells that is responsible for the GVL effect and the recipient is also associated with the major complications of allogeneic HCT, namely acute (aGVHD) and chronic graft-versus-host disease (cGVHD).
Chronic GVHD is a serious complication and is an important cause of morbidity and non-relapse mortality (NRM) in patients who survive 12 months post-transplantation (5) . Chronic GVHD is associated with a lower risk of relapse (2, 4, 6) . Despite the protective effect of cGVHD, adult patients with cGVHD experience leukemia late relapse (7) . The reduction in relapse risk may be secondary to the immune-mediated graft versus tumor (GVT) effect associated with GVHD. This effect is most prominent during the first year after allogeneic HCT when the peak incidence of relapse occurs (7, 8) . However, onsets of acute and chronic GVHD chronologically overlap and it is difficult to decipher their relative contributions to anti-leukemia effects because at the time both acute and chronic GVHD are likely active (9). Given this close time overlap between aGVHD and cGVHD, the current study sought to investigate antileukemic effects of cGVHD isolated from acute GVHD by assessing relapses and survival in allogeneic HCT recipients who were alive and relapse-free at one year following MAC transplant. In addition, we evaluated weather any specific cGVHD clinical characteristics or organ manifestations are more predominantly associated with the GVL effects of cGVHD. 6 from the CIBMTR database (n=444). The final study population consisted of a total of 7, 489 patients that received MAC regimen who were alive and free of disease at one year after transplantation.
Study definitions and endpoints
Patients were considered to have early disease if they were in first remission (acute leukemia) or first chronic phase (CML) or MDS with refractory anemia or refractory anemia with ringed sideroblasts (RA, RARS); intermediate disease: second or later complete remission (acute leukemia), second or later chronic phase/accelerated phase (CML); advanced disease: relapse or primary induction failure (acute leukemia) or blast crisis (CML) or MDS with refractory anemia with excess blasts or excess blasts in transformation (RAEB, RAEB-t). The NMDP classification of HLA matching status that allows adequate adjustment for donor-recipient HLA compatibility while accounting for best available resolution of typing was used to categorize HLA matching status as well-matched, partially-matched, or mismatched. (10). Acute GVHD was grouped as none vs. grade I vs. grade II-IV and was graded according to IBMTR criteria based on the pattern of severity of abnormalities in skin, gastrointestinal tract, and liver (11) . cGVHD was diagnosed according to standard CIBMTR criteria, which included all patients with clinical criteria of cGVHD with or without positive histology, irrespective of time of onset of symptoms (9, 12). The NIH consensus criteria were not available at the time of data collection for this analysis (13).
The primary endpoint was leukemia relapse and was defined as time to onset of disease recurrence (by hematologic or cytogenetic criteria) with treatment-related mortality (TRM) as a competing risk. Secondary endpoints were overall survival (OS), TRM, and disease-free survival (DFS). Outcomes were assessed up to 5 years post-HCT. Treatment-related mortality Death from any cause was treated as an event and surviving patients were censored at the date of last contact.
Statistical Analysis
Variables related to patient, disease, and transplant characteristics were summarized using descriptive statistics. Cumulative incidence for relapse was calculated treating TRM as a competing risk (14) . Patient-related, disease-related, and treatment-related variables were included in the multivariate analyses using a stepwise forward selection technique and P ≤ 0.01 was the criterion for inclusion in final models. Patient-and transplant-related variables tested in the models included recipient age, sex, donor type, graft type (bone marrow or peripheral blood), donor-recipient gender mismatch, donor parity, donor-recipient cytomegalovirus (CMV) serology, use of TBI, use of ATG or alemtuzumab, GVHD prophylaxis, presence and grade of prior aGVHD, and year of transplantation. Disease-related variables were diagnosis and disease status pre-transplant. Chronic GVHD-specific variables included platelet count at diagnosis (<100 x10 9 /L and ≥100 x10 9 /L), serum bilirubin at diagnosis (<1 mg/dl, 1-2 mg/dl and >2 mg/dl), type of onset of cGVHD (progressive, interrupted, de novo), Karnofsky Performance Scale/Lansky score (KPS/L) at diagnosis, severity of cGVHD at one year post-transplant (mild vs. moderate vs. severe), and organ involvement of cGVHD at one-year post-transplant.
In the multivariate analysis, all the endpoints were analyzed using the Cox proportional hazards model and all variables were tested for affirmation of the proportional hazards assumption.
Variables that did not satisfy the proportional hazards assumption were adjusted for by stratification. A stepwise model building procedure was used to develop models for each 
Results

Patients
The study included 7489 patients who were alive and disease-free one year after HCT. Patient and donor characteristics are summarized in Table 1 . The median age at HCT was 32 years for AML, 17 years for ALL, 36 years for CML, and 37 years for MDS. At one year post-HCT 44%, 41%, 54%, and 54% of the AML, ALL, CML, MDS patients, respectively, had developed cGVHD. Chronic GVHD characteristics are summarized in Table 1 .
Relapse
The cumulative incidence of relapse after the first post HCT year for each disease is shown in Table 2 . In multivariate analysis, a protective effect of cGVHD was seen only in patients with CML (RR: 0.47, 95% CI: 0.37-0.59, P <0.0001) (Figure 1 a, b) . Other factors protective against late relapse were aGVHD in the first 29 days after HCT, GVHD prophylaxis other than T-cell depletion, well-matched or partially-matched unrelated donor (URD) (as compared to HLAidentical sibling), and early disease status at transplant (Table 3, supplemental table 1) .
Transplant-related mortality and overall survival
Multivariate analysis of risk factors associated with TRM and OS are outlined in Tables 4 and 5, respectively. The presence of cGVHD was associated with a higher risk of TRM for all diseases (RR: 2.43, 95% CI: 2.09-2.82, P <0.0001) (Figure 1c , Table 4 
Chronic GVHD characteristics and impact on relapse, TRM and survival
Since the presence of cGVHD reduced the risk of relapse only in CML patients compared to those without cGVHD, we evaluated cGVHD-related variables associated with protection against relapse in CML. All types of cGVHD (i.e., mild, moderate, or severe; progressive, interrupted, or de novo), and any site of cGVHD involvement (i.e., skin or liver) provided protection against late relapse when compared to no cGVHD (supplemental Table 2 , CML patients with and without cGVHD). Pairwise comparisons performed to evaluate the impact of each subtype of cGVHD against each other (for example, the impact of presence of skin versus no skin cGVHD, or severe cGVHD versus moderate cGVHD or mild cGVHD) showed that none provided better protection. This finding was similar when the analysis on cGVHD specific variables was limited only to patients with cGVHD; in CML patients, any site or type of cGVHD provided protection against relapse, whereas in AML, ALL, and MDS patients, the presence of cGVHD at any site or type did not provide protection against relapse.
In patients with CML, cGVHD characteristics associated with higher TRM and lower OS were the presence of moderate or severe cGVHD, skin involvement, lower platelet count and KPS at cGVHD diagnosis. Moderate or severe cGVHD, lower platelet count and KPS were associated with lower DFS (supplemental table 3).
In patients with AML, ALL, and MDS, moderate or severe cGVHD, low KPS at cGVHD diagnosis, and liver or gastro-intestinal (GI) or hematologic involvement were associated with higher TRM. Higher cGVHD severity, and GI, liver and hematologic involvement were also associated with lower OS. Moderate or severe cGVHD, GI or GU or liver or hematologic involvement were associated with lower DFS (supplemental table 4).
Discussion
Allogeneic HCT is an effective immunotherapy for hematological malignancies which is mediated by GVL effect. Clinical evidence implicates acute and chronic GVHD in enhancing malignancy control and is best demonstrated in acute leukemia and CML patients after MAC (2, 4, 6, 7, 15) . GVHD is also a major complication of allogeneic HCT substantially contributing to overall TRM but its prevention or treatment with systemic immunosuppression may have harmful effects on GVL. Currently there are no established clinical strategies to guide the intensity of systemic immunosuppressive therapy for GVHD based on presumed leukemia relapse risk. It would be useful to know more precisely in which setting GVHD is most beneficial for leukemia control versus those which predominantly increase TRM. Since occurrence and effects of acute and chronic GVHD overlap during the first year post-transplant, it is difficult to study antitumor effects attributed specifically to cGVHD in the proximity of acute GVHD and therapy related systemic immunosuppression. We focused here on assessing cGVHD effects isolated from acute GVHD by studying only patients who were alive and free of disease at one year post-HCT when acute GVHD effects were sufficiently distant.
This current study demonstrates the protective effect of cGVHD on late relapse only in patients with CML. A protective effect of cGVHD against late relapse was not seen in AML, ALL, or MDS. Data in the current study also confirm that the presence of cGVHD is associated with significantly higher TRM and worse OS across all diseases studied (9).
Several retrospective studies have demonstrated that cGVHD decreases relapses in AML, ALL, and especially in CML (2, 4, 6, 16) . These studies evaluated anti-leukemia effects from time of transplant to relapse and did not account for possible confounding effects by acute GVHD. The lack of impact of cGVHD on late relapse in acute leukemia and MDS in this study may be due to differences in biology and susceptibility to immune responses in each disease.
Relapse of leukemia following allo-HCT could be due to failure of GVL or immune clonal escape of the leukemia cells including down regulation of MHC class I and II antigens, associated with a decreased ability to stimulate allo-geneic proliferative T cell responses, and decreased susceptibility to lysis by cytotoxic T lymphocytes or natural killer cells. Since GVL requires time to become fully established after immune reconstitution, the degree to which GVL 
12
can control leukemia after allo-HCT may depend on the growth kinetics of the leukemia. Thus, patients with CML compared to patients with acute leukemia may be more susceptible to a durable GVL effect because of their slower pace of proliferation.
The majority of leukemia relapses occur within the first year post-HCT. Similar risk of relapse has been observed using unrelated donor transplant or HLA-identical sibling donors in AML, ALL and CML (15) . In the current study, late relapses occurred in all leukemia types and a beneficial cGVHD effect was detected only in those with CML. Differential susceptibility to GVL effects has been observed after administration of donor leukocyte infusion (DLI), which is more effective in relapsed CML than other hematologic malignancies (17) (18) (19) (20) .
Despite the expectation of protective effects of cGVHD in all diseases, the five-year incidence of relapse was only lower in CML. For this reason we analyzed weather any of the cGVHD specific clinical characteristics or organ manifestations, showed a more dominant association with relapse in CML patients, as such findings could lead towards a better understanding of GVL mechanisms dependent on cGVHD. We found that all sites and types of cGVHD involvement equally affected relapse, suggesting that CML patients with minimal cGVHD clinical manifestation may benefit from its antitumor effect.
This study has several limitations. Chronic GVHD was not classified here per NIH consensus criteria in the CIBMTR database at the time and the data analysis used retrospective design.
Specific treatment information for cGVHD is not ascertained and variability in treatment modalities for acute and chronic GVHD during the first year post-HCT may have affected the incidence of late relapse. However, any such effects should be balanced out by the very large number of patients in this study cohort. This study was selected to evaluate a specific question:
impact of cGVHD on late relapse (after one year post HCT). To classify patients accurately and determine cut points for analysis, we evaluated time to onset of cGVHD. Most patients (>95%)
developed cGVHD within one year of HCT. Hence, we chose this time point for evaluation.
Patients who developed cGVHD after one year and were eligible to be included in the dataset were classified as non-cGVHD patients. This may also have affected the analysis. In addition, patients who developed cGVHD during the first year after allogeneic HCT and were successfully treated for their cGVHD may have been reported to the registry as not having active cGVHD.
This would be quite unlikely, considering the usually slowly receding nature of cGVHD, and the standard procedure of 12 months registry data collection which requires reporting events during the whole previous observation period.
Data on the use of tyrosine kinase inhibitors (TKI) prior to allogeneic HCT was not available in patients with CML, however, during this study period of 1995-2004, only a minority of patients could have had prior TKI exposure.
This report findings only applies to cGVHD effects after MAC. The more recently expanded use of reduced intensity conditioning (RIC) or truly non-myeloablative conditioning regimens has shifted some of the burden of tumor cell kill after allogeneic HCT from the conditioning regimen to the immune-mediated GVL effects (18). Weisdorf et al recently investigated the effects of acute and chronic GVHD on late relapse after RIC and MAC conditionings regimens in patients with AML and MDS (21) . Similar to this current study, in AML and MDS patients following MAC they found the risk of late relapse not significantly affected by cGVHD. However, following RIC regimens, in patients who had both acute and cGVHD late relapse rates were significantly lower. Baron et al also evaluated the GVL effects of cGVHD in AML patients that underwent RIC allo-HCT. In a landmark analysis of patients who were leukemia-free at 18 months after HCT, patients with cGVHD before the landmark day had a lower relapse rate than 14 those without cGVHD (22) . These data combined, demonstrate a differential effect of cGVHD on late relapse based on the type of conditioning used in allo-HCT.
In conclusion, this study suggest that cGVHD impact on late relapse of leukemia after MAC HCT is not clinically relevant in AML, ALL and MDS since the beneficial effects on late relapse are confined to patients with CML. The potentially positive impact of the GVL effects on survival after MAC HCT are blunted by a higher cGVHD-related mortality resulting with higher TRM and lower OS for all studied diseases. These data may have practical clinical implications as developing more aggressive strategies to prevent and treat cGVHD may be justified for hematological malignancy patients after HCT with MAC regimens. Future studies aiming to advance the understanding of the cGVHD role in controlling hematologic malignancy should be done prospectively in contemporary patient cohorts and incorporating high level of detail on cGVHD clinical data collection. 
